How to buy PhaseBio Pharmaceuticals stock

PhaseBio Pharmaceuticals, Inc is a biotechnology business based in the US. PhaseBio Pharmaceuticals shares (PHAS) are listed on the NASDAQ and all prices are listed in US Dollars. PhaseBio Pharmaceuticals employs 50 staff and has a trailing 12-month revenue of around 0.00.

PhaseBio Pharmaceuticals share price

Use our graph to track the performance of PHAS stocks over time.

PhaseBio Pharmaceuticals shares at a glance

• Key figures

Information last updated 2021-04-23.

52-week range	$2.60 - $6.35
50-day moving average	$3.55
200-day moving average	$3.75
Wall St. target price	$15.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.62

Buy PhaseBio Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy PhaseBio Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of PhaseBio Pharmaceuticals, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

PhaseBio Pharmaceuticals financials

Revenue TTM	$320,000
Gross profit TTM	$-71,768,000
Return on assets TTM	-79.84%
Return on equity TTM	-566.86%
Profit margin	0%
Book value	$0.15
Market capitalisation	$143.1 million

TTM: trailing 12 months

Shorting PhaseBio Pharmaceuticals shares

There are currently 3.2 million PhaseBio Pharmaceuticals shares held short by investors – that's known as PhaseBio Pharmaceuticals's "short interest". This figure is 4.6% up from 3.1 million last month.

There are a few different ways that this level of interest in shorting PhaseBio Pharmaceuticals shares can be evaluated.

PhaseBio Pharmaceuticals's "short interest ratio" (SIR)

PhaseBio Pharmaceuticals's "short interest ratio" (SIR) is the quantity of PhaseBio Pharmaceuticals shares currently shorted divided by the average quantity of PhaseBio Pharmaceuticals shares traded daily (recently around 1.1 million). PhaseBio Pharmaceuticals's SIR currently stands at 2.95. In other words for every 100,000 PhaseBio Pharmaceuticals shares traded daily on the market, roughly 2950 shares are currently held short.

However PhaseBio Pharmaceuticals's short interest can also be evaluated against the total number of PhaseBio Pharmaceuticals shares, or, against the total number of tradable PhaseBio Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case PhaseBio Pharmaceuticals's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 PhaseBio Pharmaceuticals shares in existence, roughly 70 shares are currently held short) or 0.1023% of the tradable shares (for every 100,000 tradable PhaseBio Pharmaceuticals shares, roughly 102 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against PhaseBio Pharmaceuticals.

Find out more about how you can short PhaseBio Pharmaceuticals stock.

PhaseBio Pharmaceuticals share dividends

We're not expecting PhaseBio Pharmaceuticals to pay a dividend over the next 12 months.

PhaseBio Pharmaceuticals share price volatility

Over the last 12 months, PhaseBio Pharmaceuticals's shares have ranged in value from as little as $2.6 up to $6.35. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while PhaseBio Pharmaceuticals's is 1.7362. This would suggest that PhaseBio Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

PhaseBio Pharmaceuticals overview

PhaseBio Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc.

Frequently asked questions

• What percentage of PhaseBio Pharmaceuticals is owned by insiders or institutions?

  Currently 7.226% of PhaseBio Pharmaceuticals shares are held by insiders and 50.888% by institutions.

• How many people work for PhaseBio Pharmaceuticals?

  Latest data suggests 50 work at PhaseBio Pharmaceuticals.

• When does the fiscal year end for PhaseBio Pharmaceuticals?

  PhaseBio Pharmaceuticals's fiscal year ends in December.

• Where is PhaseBio Pharmaceuticals based?

  PhaseBio Pharmaceuticals's address is: 1 Great Valley Parkway, Malvern, PA, United States, 19355

• What is PhaseBio Pharmaceuticals's ISIN number?

  PhaseBio Pharmaceuticals's international securities identification number is: US7172241090

• What is PhaseBio Pharmaceuticals's CUSIP number?

  PhaseBio Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 717224109